48,205 Merck & Co., Inc. $MRK Shares Sold by Courier Capital LLC

Key Points

• Courier Capital sharply reduced its Merck position: The firm sold 48,205 shares during the third quarter, cutting its holdings by 89.9% to 5,398 shares valued at approximately $784,000.
• Institutional ownership remains substantial: Institutional investors own 76.07% of Merck, with BlackRock, State Street and Wellington among the largest holders, despite some funds and insiders recently selling shares.
• Merck faces mixed market signals: The stock recently traded at $141.97, while analysts maintain a “Moderate Buy” consensus with an average price target of $151.92; upcoming oncology data and earnings could serve as important catalysts.

Courier Capital LLC trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 89.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,398 shares of the company's stock after selling 48,205 shares during the period. Courier Capital LLC's holdings in Merck & Co., Inc. were worth $784,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. increased its position in Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the last quarter. State Street Corp lifted its position in Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company's stock valued at $15,573,754,000 after purchasing an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock worth $11,083,033,000 after buying an additional 1,934,312 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock worth $3,701,831,000 after buying an additional 2,919,780 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Merck & Co., Inc. by 3.5% in the 4th quarter. Invesco Ltd. now owns 20,546,185 shares of the company's stock worth $2,162,691,000 after buying an additional 701,249 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Oncology pipeline update: Merck will present first-time results from three pivotal Phase 3 trials, along with more than 90 additional abstracts covering over 20 tumor types, at the ESMO 2026 Congress on October 23–27. The event could provide important evidence of Merck’s ability to replenish growth as investors look beyond its existing portfolio. Merck ESMO 2026 oncology pipeline update
• Positive Sentiment: Upcoming earnings catalyst: Merck is expected to report third-quarter results in roughly two weeks, with analysts forecasting single-digit EPS growth. The report may clarify operating trends, full-year guidance and the effect of recent pipeline developments. Merck next earnings report expectations
• Neutral Sentiment: Board addition: Merck elected Paul J. Diaz, a healthcare executive, to its board of directors. The appointment may strengthen the board’s operating and healthcare expertise, but no immediate financial impact was announced. Paul J. Diaz elected to Merck board
• Neutral Sentiment: Analyst price targets remain mixed: Citi raised its target to $145 while retaining a neutral rating, whereas RBC lowered its target to $145 and maintained a sector-perform rating. These changes suggest limited near-term conviction despite the stock’s strong six-month performance.
• Negative Sentiment: Remigromig concerns: Jefferies cut its peak sales forecast for Merck’s experimental diabetic macular edema treatment by 60%. Although the Phase 2b/3 study met its non-inferiority goal against Lucentis, the drug showed smaller numerical vision improvements and raised efficacy and safety concerns, reducing its perceived commercial opportunity. Jefferies cuts remigromig sales forecast
• Negative Sentiment: Lower earnings estimates: Erste Group reduced its FY2026 EPS estimate to $2.73 from $2.75 and its FY2027 estimate to $9.47 from $9.52. The modest cuts reinforce pressure on expectations, even though broader estimates remain higher than the current-year consensus cited in the reports.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Chirfi Guindo sold 15,000 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president owned 46,613 shares of the company's stock, valued at $6,106,303. This trade represents a 24.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 in the last three months. 0.17% of the stock is owned by insiders.

Merck & Co., Inc. Trading Down 2.4%

MRK traded down $3.48 during trading on Tuesday, reaching $141.97. The company had a trading volume of 8,377,313 shares, compared to its average volume of 10,630,645. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The business has a 50 day simple moving average of $144.25 and a 200-day simple moving average of $128.57. The stock has a market cap of $350.27 billion, a P/E ratio of 113.58, a PEG ratio of 6.58 and a beta of 0.21. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. During the same quarter in the previous year, the business posted $2.13 earnings per share. The business's revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 2.66 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.4%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is presently 272.00%.

Analyst Upgrades and Downgrades

MRK has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an "overweight" rating in a report on Monday, October 5th. Citigroup increased their price target on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the company a "neutral" rating in a report on Monday. Weiss Ratings upgraded Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 25th. Sanford C. Bernstein boosted their price objective on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a "market perform" rating in a research note on Tuesday, August 4th. Finally, Daiwa Securities Group raised Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price objective on the stock in a research note on Wednesday, August 12th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $151.92.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.